PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po)[1].
0.01EURAsk for quotation
Preț : Ask for quotation
Disponibil
Număr Catalog 804-HY-149539CategorieAfaceri și industrie > Știință și laboratorFurnizorMedChemExpressGentaurDimensiuneGet quoteTipsingle